Only in Titles

           Search results for: HBs Ag one step (screening)   

paperclip

#28567194   2017/06/01 Save this To Up

Prevalence of antibody to hepatitis B core antigen among hepatitis B surface antigen-negative blood donors in Ilorin, Nigeria: A cross-sectional study.

Post-transfusion hepatitis occurs even with stringent donor selection criteria and screening for hepatitis B surface antigen (HBsAg). The objective of this study was to determine the prevalence of antibody to hepatitis B core antigen (anti-HBc) in HBsAg-negative blood donors.

1716 related Products with: Prevalence of antibody to hepatitis B core antigen among hepatitis B surface antigen-negative blood donors in Ilorin, Nigeria: A cross-sectional study.

anti H inh human blood an Human Anti-Core Antigen o Anti-Hepatitis B Surface Anti-Hepatitis B Surface Hepatitis B Core Antigen Hepatitis B Core Antigen Hepatitis B Core Antigen Hepatitis B Core Antigen HCV core recombinant anti anti A1, A2 human blood a anti A1, A2, A3 human blo anti B human blood antige

Related Pathways

paperclip

#27460099   2016/07/27 Save this To Up

Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody.

Hepatitis B surface antigen (HBsAg) is used as a clinical marker of hepatitis B virus (HBV) infection. However, conventional HBsAg assays have so far failed to accurately detect HBsAg in blood because of interference by patient-derived antibodies against HBsAg (HBsAb).

2930 related Products with: Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody.

Anti-Hepatitis B Surface Anti-Hepatitis B Surface MOUSE ANTI BORRELIA BURGD Rabbit Anti-Polyprotein(H Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Recombinant Hepatitis B S Recombinant Hepatitis B S Human Hepatitis B Surface Human anti-Hepatitis B Su Hepatitis B surface Ag (H Hepatitis B surface Ag (H

Related Pathways

paperclip

#26857933   2016/02/09 Save this To Up

Seroprevalence of hepatitis B virus serological markers among pregnant Nigerian women.

Chronic hepatitis B infection is a global problem; however, Asia and sub-Saharan Africa are most affected by it. Hepatitis B status of pregnant women is essential for the effective management of the disease and prevention of mother to child transmission.

2370 related Products with: Seroprevalence of hepatitis B virus serological markers among pregnant Nigerian women.

Rabbit Anti-Polyprotein(H Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V HbcAg - Hepatitis B Viru HbcAg - Hepatitis B Viru HbcAg - Hepatitis B Viru Tick born encephalitis vi Viral antibodies, anti-R anti Rotavirus p42 IgG2a Hepatitis C Virus antibod Hepatitis B Virus antibod Hepatitis B Virus antibod

Related Pathways

paperclip

#26711310   2016/02/13 Save this To Up

Array-in-well platform-based multiplex assay for the simultaneous detection of anti-HIV- and treponemal-antibodies, and Hepatitis B surface antigen.

Multiplex assays detecting sets of related clinical analytes simultaneously can save considerable amount of time and resources. Array-in-well (AIW) is a powerful platform for the multiplex detection of different analytes where microarrays can be printed at the bottom of microtiter wells, thus combining the potential of microarrays with the ease of handling microtiter wells. We have developed a single-step AIW assay for the simultaneous screening of HIV, Treponema pallidum subspecies pallidum (causing syphilis) and Hepatitis B virus infections targeting the specific detection of anti-HIV- and treponemal-antibodies and Hepatitis B surface antigen (HBsAg), respectively, using two different fluorescent label technologies i.e. DyLight 633 and europium nanoparticle. Double-antigen assay formats were used for anti-HIV- and treponemal-antibody detection that can simultaneously detect both IgG and IgM, and thus reduce the window period of detection. AIW assay was evaluated with well characterized serum/plasma samples (n=111), and the qualitative results were in near complete agreement with those of the reference assays. The AIW assay exhibited 100% sensitivities for all three analytes, and 100% specificities for anti-HIV antibodies and HBsAg, and 98.6% specificity for treponemal antibodies. The limit of detection of HBsAg in AIW assay was 0.18 ng/ml. This high performing AIW assay has the potential to be used as a multiplex screening test for these three infections.

1971 related Products with: Array-in-well platform-based multiplex assay for the simultaneous detection of anti-HIV- and treponemal-antibodies, and Hepatitis B surface antigen.

Rabbit Anti-Rat Androgen MarkerGeneTM Fluorescent Blood Group Antibodies a MOUSE ANTI BORRELIA BURGD Rabbit Anti-Human Androge Goat Anti-Human Androgen Goat Anti-HIV-1 gp120 [+B Goat Anti-HIV-1 gp41 [+Bi Mouse Anti-Bacteroides th Mouse Anti-EBV Early Anti Mouse Anti-EBV Early Anti Anti-Hepatitis B Surface

Related Pathways

paperclip

#25970703   2015/06/03 Save this To Up

Selection of HBsAg-Specific DNA Aptamers Based on Carboxylated Magnetic Nanoparticles and Their Application in the Rapid and Simple Detection of Hepatitis B Virus Infection.

Aptamers are short single-stranded DNA or RNA oligonucleotides and can be selected from synthetic combinatorial libraries in vitro. They have a high binding affinity and specificity for their targets. Agarose gels, nitrocellulose membranes, and adsorptive microplates are often used as carriers to immobilize targets in the SELEX (systematic evolution of ligands by exponential enrichment) process, but the subsequent separation step is tedious and time-consuming. Therefore, we used magnetic nanoparticles (MNPs) as carriers to immobilize the target, hepatitis B surface antigen (HBsAg), which is convenient for fast magnetic separation. In this study, we first selected DNA aptamers against HBsAg by immobilizing HBsAg on the surface of carboxylated MNPs. The ssDNA library of each selection round was prepared by asymmetric PCR amplification for the next selection round. To obtain aptamer sequences, the final selected products were purified by gel electrophoresis, then cloned, and sequenced. DNA aptamers that specifically bind to HBsAg were successfully obtained after 13 selection rounds. The selected aptamers were used to construct a chemiluminescence aptasensor based on magnetic separation and immunoassay to detect HBsAg from pure protein or actual serum samples. There was a linear relationship between HBsAg concentration and chemiluminescent intensity in the range of 1-200 ng/mL. The aptasensor worked well even in the presence of interfering substances and was highly specific in the detection of HBsAg in serum samples, with a detection limit 0.1 ng/mL lower than the 0.5 ng/mL limit of an ELISA in use at the hospital. This aptasensor can contribute to better detection of hepatitis B virus infection.

2442 related Products with: Selection of HBsAg-Specific DNA Aptamers Based on Carboxylated Magnetic Nanoparticles and Their Application in the Rapid and Simple Detection of Hepatitis B Virus Infection.

pCAMBIA0105.1R Vector, (G MOUSE ANTI BOVINE ROTAVIR Human Epstein-Barr Virus Mouse Epstein-Barr Virus TGF beta induced factor 2 Inhibin beta-A antibody S Influenza A Virus Hemaggl BriteRuler™ 1 kb DNA La BYL-719 Mechanisms: PI3K- GSK-2636771 Mechanisms: P 17β-Acetoxy-2α-bromo-5 3-O-Acetyl-17-O-tert-buty

Related Pathways

paperclip

#25892477   2015/05/19 Save this To Up

Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping.

Hepatitis B virus (HBV) genotyping plays an important role in the clinical management of chronic hepatitis B (CHB) patients. However, the current nucleic acid based techniques are expensive, time-consuming, and inconvenient. Here, we developed a novel DNA-independent HBV genotyping tool based on a one-step fluorescent lateral flow immunoassay (LFIA). Epitope-targeting immunization and screening techniques were used to develop HBV genotype specific monoclonal antibodies (mAbs). These mAbs were used to develop a multitest LFIA with a matched scanning luminoscope for HBV genotyping (named the GT-LFIA). The performance of this novel assay was carefully evaluated in well-characterized clinical cohorts. The GT-LFIA, which can specifically differentiate HBV genotypes A, B, C, and D in a pretreatment-free single test, was successfully developed using four genotype specific mAbs. The detection limits of the GT-LFIA for HBV genotypes A, B, C, and D were 2.5-10.0 IU HBV surface antigen/mL, respectively. Among the sera from 456 CHB patients, 439 (96.3%; 95% confidence interval (CI), 94.1-97.8%) were genotype-differentiable by the GT-LFIA and 437 (99.5%; 95% CI, 98.4-99.9%) were consistent with viral genome sequencing. In the 21 patients receiving nucleos(t)ide analogue therapy, for end-of-treatment specimens that were HBV DNA undetectable and were not applicable for DNA-dependent genotyping, the GT-LFIA presented genotyping results that were consistent with those obtained in pretreatment specimens by viral genome sequencing and the GT-LFIA. In conclusion, the novel GT-LFIA is a convenient, fast, and reliable tool for differential HBV genotyping, especially in patients with low or undetectable HBV DNA levels.

2593 related Products with: Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping.

Rabbit Anti-Polyprotein(H Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V MarkerGeneTM Fluorescent HbcAg - Hepatitis B Viru HbcAg - Hepatitis B Viru HbcAg - Hepatitis B Viru Formalin (10% Neutral Bu Formalin (10% Neutral Bu Flow Cytometry Staining B Tick born encephalitis vi MOUSE ANTI BOVINE ROTAVIR

Related Pathways

paperclip

#24987752   2014/07/29 Save this To Up

Aptamer-based competitive binding assay for one-step quantitation of hepatitis B surface antigen.

An aptamer-based competitive binding assay for one-step (i.e. no requirement of pre-treatment) quantitation of target molecules of interest has been developed. This method has been successfully employed for the fast and sensitive detection of the surface antigen of the hepatitis B virus (HBsAg). The key features of our method include its low intrinsic background noise, low costs, high resolution, and high sensitivity, enabling the detection of as low as 1.25 mIU mL(-1), approximately 40-fold better than that of the most widely used Abbott Architect assay for HBsAg detection, without the tedious extraction and/or washing procedures. Moreover, this assay has better recovery and accuracy than that of conventional competitive binding assay or others for HBsAg quantitation.

1260 related Products with: Aptamer-based competitive binding assay for one-step quantitation of hepatitis B surface antigen.

MarkerGeneTM Fluorescent MOUSE ANTI BORRELIA BURGD Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Live Cell C Cell Meter™ Annexin V B

Related Pathways

paperclip

#24984327   2014/07/02 Save this To Up

[Recent developments in serologic and molecular diagnosis of hepatitis B and C].

The 2013 Update of the Croatian Guidelines for the Diagnosis and Treatment of Viral Hepatitis summarizes recent developments in the diagnosis of hepatitis B and C. Determination of HBsAg, anti-HBc and anti-HBs is the initial step in the diagnostic workup of acute and chronic hepatitis B. Other hepatitis B serologic markers should be analyzed in the second stage of the diagnostic workup in HBsAg and/or anti-HBc positive patients. A positive anti-HBc finding should be followed by HBV DNA quantification. HBsAg quantification is complimentary to the HBV DNA quantification and is used: (i) to differentiate between inactive HBsAg carriers and active chronic HBeAg-negative hepatitis B in patients with HBV DNA < 2000 IU/mL; and (ii) for treatment monitoring in patients with chronic hepatitis B receiving pegylated interferon-alpha. Real-time PCR remains the method of choice for detection and quantification of HBV DNA. The first step in HCV testing is determination of specific antibodies via screening assays, enzyme immunoassays or point-of-care assays. All persons with positive results of anti-HCV screening assays should be additionally tested for HCV RNA or presence of HCV viral capsid antigen. Confirmatory anti-HCV assays should be used as additional assays for confirmation of reactive results obtained by screening enzyme immunoassays in HCV RNA-negative persons only. Molecular assays with identical lower limit of detection (LLOD) and lower limit of quantification are recommended for monitoring of viral kinetics during chronic hepatitis C triple therapy. HCV resistance testing to protease inhibitors is not part of the recommended diagnostic monitoring of patients receiving triple therapy. HCV subtyping is currently not recommended as part of pretreatment diagnostic algorithm due to currently insufficient evidence on its clinical usefulness. IL-28 genotype is an important predictor of SVR in patients treated with a combination of interferon-alpha and ribavirin as well as in patients with HCV genotype 1 receiving triple therapy. IL-28B genotyping is recommended as part of pretreatment diagnostic workup in patients with chronic hepatitis C and is a particularly important parameter for recommending double versus triple therapy in treatment-naïve patients with chronic hepatitis C.

1594 related Products with: [Recent developments in serologic and molecular diagnosis of hepatitis B and C].

17β-Acetoxy-2α-bromo-5 3-O-Acetyl-17-O-tert-buty Bovine Androstenedione,AS Rabbit Anti-Rat Androgen Epiandrosterone (3 beta H BCIP INT Solution BCIP INT Solution BCIP INT Solution Growth Differentiation Fa CELLKINES Natural Human I Human Macrophage Inflamma Human Macrophage Inflamma

Related Pathways

paperclip

#24976705   2014/06/30 Save this To Up

Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.

Patients with hepatocellular carcinoma (HCC) often experience hepatic morbidity. Hepatitis B virus (HBV) reactivation is well documented as a serious hepatic morbidity during anti-cancer therapy. Reported rates of HBV reactivation in chronic carriers with HCC undergoing chemotherapy range from 4%-67%. Apart from chemotherapy, HBV reactivation has been increasingly identified in settings of hepatectomy and local ablation therapies. The rates of HBV reactivation vary with different levels of immunosuppression and depend on treatment, viral factors, and patient characteristics. The principal concern relating to reactivation is that a substantial proportion of patients with reactivation suffer from liver dysfunction during therapy, which often leads to disruption of planned, potentially life-prolonging treatments, adversely affecting the patients' final outcome. The first step in the management of HBV reactivation is identification of patients at risk of reactivation by testing for HBV serology prior to commencing anti-cancer therapy. Although it is a serious complication, HBV reactivation is preventable with prophylactic anti-HBV drugs. Multiple publications have shown the benefit of prophylactic or preemptive antiviral therapy in this setting and justified such an approach before the start of therapy. Given the tumors and underlying cirrhosis, long-term use of antivirals with high potency and low risk of resistance is recommended in patients with HCC. This topic review will summarize the epidemiology, pathogenesis, and clinical issues related to HBV reactivation in HCC patients, and will discuss proper management against HBV reactivation during anti-cancer therapy for HCC.

2503 related Products with: Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.

Breast cancer and matched Breast cancer and matched Multiple organ cancer tis Lung cancer tissue array Colon cancer tissue array Kidney cancer tissue arra Ovary cancer tissue array Bladder cancer tissue arr Bladder cancer tissue arr Bladder cancer tissue arr Breast cancer and matched Breast cancer, carcinoma

Related Pathways

  •  
  • No related Items
paperclip

#24260439   2013/11/22 Save this To Up

Negative interference in serum HBsAg ELISA from rheumatoid factors.

RF(Rheumatoid factor) is usually thought to cause positive interference in immunoassay. Recently, our study showed that high-concentration RFs caused negative interference as well as positive interference in serum HBsAg(Hepatitis B surface antigen) ELISA(Enzyme-linked immunosorbent assay), but it is unclear that RF causing negative interference is an anomaly produced by a certain ELISA kit or a common property of most of HBsAg ELISA kits.

2664 related Products with: Negative interference in serum HBsAg ELISA from rheumatoid factors.

Human interleukin 2(IL-2) Bovine prolactin-induced Sterile filtered goat se Sterile filtered goat se Sterile filtered mouse s Sterile filtered rat ser HBV-3 panel test, HBsAg H Rat inositol 1,4,5,-trisp Rat TGF-beta-inducible ea Rat TGF-beta-inducible ea Rat Interleukin 1(IL-1)EL Rat Interleukin 13(IL-13)

Related Pathways